Table 3.

Multivariate Cox proportional hazard models for overall survival (OS) and progression-free survival (PFS)

Variables	PFS		OS
	Hazard ratio (95% CI)	p-value	Hazard ratio (95% CI)	p-value
Central type (n = 28)
Stage	4.43 (1.42–15.00)	0.01a	26.05 (4.28–509.30)	<0.0001a
NSE	2.30 (0.86–6.55)	0.10	2.03 (0.59–7.97)	0.27
P-SUVmax	1.06 (0.39–2.86)	0.900	1.07 (0.34–3.43)	0.90
Stage	4.14 (1.47–12.97)	0.0068a	24.86 (4.34–475.1)	<0.0001a
NSE	2.60 (0.95–7.38)	0.062	2.19 (0.63–8.45)	0.22
H-SUVmax	0.76 (0.29–1.96)	0.56	0.89 (0.29–2.86)	0.85
Stage	4.04 (1.41–12.80)	0.0091a	23.44 (3.97–453.6)	<0.0001a
NSE	0.87 (0.19–5.57)	0.88	0.36 (0.047–4.56)	0.39
WB-MTV	3.25 (0.51–18.25)	0.21	7.90 (0.55–83.08)	0.12
Stage	3.91 (1.33–12.58)	0.013a	23.35 (3.88–453.54)	<0.0001a
NSE	1.92 (0.64–5.73)	0.24	1.14 (0.25–5.90)	0.87
WB-TLG	1.60 (0.51–4.91)	0.42	2.60 (0.49–14.10)	0.26
Peripheral type (n = 41)
Stage	2.39 (0.76–8.65)	0.14	5.99 (1.37–40.16)	0.015a
NSE	1.48 (0.45–4.36)	0.51	1.13 (0.19–5.45)	0.89
P-SUVmax	1.18 (0.54–2.59)	0.68	0.86 (0.33–2.30)	0.76
Stage	2.33 (0.82–7.80)	0.12	5.09 (1.25–29.99)	0.021a
NSE	1.48 (0.46–4.25)	0.50	1.09 (0.20–5.02)	0.92
H-SUVmax	1.47 (0.72–3.08)	0.29	1.43 (0.58–3.75)	0.44
Stage	1.31 (0.45–4.44)	0.64	2.85 (0.77–14.43)	0.12
NSE	0.94 (0.30–2.85)	0.92	0.49 (0.10–2.52)	0.49
WB-MTV	4.39 (1.40–14.13)	0.011a	6.85 (1.30–36.71)	0.023a
Stage	1.30 (0.44–4.53)	0.66	2.84 (0.77–14.70)	0.13
NSE	0.96 (0.30–2.91)	0.94	0.49 (0.10–2.56)	0.39
WB-TLG	4.15 (1.24–13.79)	0.021a	6.75 (1.20–36.86)	0.031a

CI, confidence interval; H-SUV_max, maximum standardized uptake value of the highest lesion of the disease; NSE, neuron-specific enolase; P-SUV_max, maximum standardized uptake value of the primary tumour lesion; WB-MTV, whole-body metabolic tumour volume; WB-TLG, whole-body total lesion glycolysis.

^ap < 0.05.